tiprankstipranks
Trending News
More News >

Lipella Pharmaceuticals to present Phase 2a data for LP-310

Lipella Pharmaceuticals (LIPO) announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 for the treatment of Oral Lichen Planus will be presented at the 2025 joint international meeting of the American Academy of Oral Medicine (AAOM) and the European Association of Oral Medicine in Las Vegas. Treatment at the 0.50 mg dose demonstrated statistically significant improvements in multiple endpoints: Investigator Global Assessment: Improved from 3.42 at baseline to 1.71 at Week 4; REU Score: Reduced from 26.91 to 11.88 at Week 4; Oral Lichen Planus Symptom Severity Measure: Dropped from 14.92 to 4.88 at Week 4; Pain Numerical Rating Scale: Improved from 6.42 to 2.25 at Week 4.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1